|
Antibody Production in Immune Disorders Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Antibody Production in Immune Disorders conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Antibody Production in Immune Disorders Clinical research trials and Antibody Production in Immune Disorders medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Antibody Production in Immune Disorders. Antibody Production in Immune Disorders Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Antibody Production in Immune Disorders clinical trial. Test subjects typically obtain the finest healthcare available for their Antibody Production in Immune Disorders condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Antibody Production in Immune Disorders  Antibody Production in Immune Disorders
Antibody Production in Immune Disorders
For Condition: Immunologic Disease
Status: Recruiting
Sponsor(s): National Human Genome Research Institute (NHGRI) ,
Synopsis: This study will evaluate immune function in people with a known or suspected immune disorder. It will determine participants' immune response to vaccines by measuring blood antibody levels after vaccination. Patients enrolled in a NIH protocol involving immune reconstitution (bone marrow transplantation or gene therapy) for a known or suspected primary immune disorder may be eligible for this study. Participants may be asked to have more than one vaccine, based on their age, use of IVIG, past immunization history and underlying immune problem. The possible vaccinations include: • (Bullet) Rabies vaccine • (Bullet) Diphtheria and tetanus booster • (Bullet) 23 valent pneumococcal polysaccharide vaccine • (Bullet) Pneumococcal 7-valent conjugate vaccine The diphtheria, tetanus, pneumococcus and rabies vaccines are approved by the Food and Drug Administration (FDA) and used routinely to protect against disease. Study participants will have a blood sample drawn before vaccination. The number of additional samples collected will vary according to the vaccines administered; 1 for rabies; 1 for tetanus; and 1 to 2 for the pneumococcal vaccines. Each sample will be up to 5 teaspoonfuls. Participation in the study may last up to a year, depending on the blood sampling scheduling
Details: The purpose of this study is to evaluate antibody responses in patients with known or suspected primary immune disorders. Up to 50 subjects per year are expected to be enrolled. It is anticipated that subjects will be referred who have been evaluated by any of several investigators at NIH studying inherited disorders of the immune system under their own protocols. This will be an open label prospective study investigating the functional status of the adaptive immune system. After giving standard vaccines, we will test specific antibody production. The vaccines include licensed and universally mandated diphtheria and tetanus toxoid, two licensed pneumococcal vaccine formulations, and the rabies vaccine licensed in 1997 (not the formerly available reaction-prone formulation). To measure these specific antibody levels, we will obtain peripheral blood samples from subjects before vaccination and at specific time intervals after vaccination. Antibody titers will be obtained from commercial labs, the Maryland State Lab (for rabies titers), or CLIA approved labs. Since antibody production depends on both B cells (which secrete antibody molecules) and T cells (which provide helper factors for B cells), the vaccinations selected for use will tell us about the function of multiple lymphocyte lineages and define a range of functional defects in immunity. Subjects may be offered one or more of the vaccines based on available information about their exposure history and their immune status, and the vaccines may be offered sequentially or in combination to shorten study time and streamline blood samples required.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Individuals being evaluated by NIH investigators for known or suspected primary immune disorders. Patients undergoing immune reconstitution in separate NIH protocols for the treatment of their primary immune disorder (including bone marrow transplantation or gene therapy). EXCLUSION CRITERIA: HIV infection. Active malignancy. Immunosuppressive therapy, other than steroids. Symptomatic cardiac disease or ongoing treatment for same. Pregnant or lactating women (due to restrictions on use of vaccines). Surgery during the two weeks prior to entry. Serious, ongoing, or uncontrolled infections. Platelet count less than 40,000/micro L. Any other major illness which, in the investigator's judgment, may substantially increase the risk associated with the patient's participation in this study. History of previous systemic reaction to the particular vaccine product being considered for administration. Known immediate hypersensitivity reactions to egg protein will make a patient ineligible for rabies immunization.
Total Enrollment: 50
Location and Contact Information:
National Human Genome Research Institute (NHGRI) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 010226; 01-HG-0226
Study Start Date: September 3, 2001
Record last reviewed: August 20, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00023504
Other Immunologic Disease Studies:
1. Use of G-CSF to Obtain Blood Cell Precursors
2. Antibody Production in Immune Disorders
3. Consequences of Conjugal Bereavement in Adults
Related Studies:
Other Immunologic Disease Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Antibody Production in Immune Disorders
|
|
|
|
|
|
|
|
